Century Therapeutics (IPSC) Net Income towards Common Stockholders (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$90.9 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 218.75% year-over-year to -$90.9 million in Q1 2026; TTM through Mar 2026 was -$167.4 million, a 677.04% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, up 101.64% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$90.9 million, down from -$9.5 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for IPSC reached as high as $76.6 million in Q1 2025 and fell as low as -$90.9 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$28.5 million across 5 years, with a median of -$31.7 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders jumped 372.82% in 2025 and slumped 218.75% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$31.7 million in 2022, then decreased by 24.35% to -$39.4 million in 2023, then climbed by 9.45% to -$35.7 million in 2024, then surged by 73.24% to -$9.5 million in 2025, then slumped by 852.26% to -$90.9 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$90.9 million in Q1 2026, -$9.5 million in Q4 2025, and -$34.4 million in Q3 2025.